Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 11, 2026, 12:36 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1513–1536 of 3,925 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: HTN Clear all

Conditions: Glaucoma, Open-Angle Ocular Hypertension
Interventions: Bimatoprost SR, Sham Bimatoprost SR, Selective Laser Trabeculoplasty, Sham Selective Laser Trabeculoplasty; Drug · Procedure
Lead sponsor: Allergan; Industry
Eligibility: 18 Years and older
Enrollment: 144 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2021
U.S. locations: 21
States / cities: Dothan, Alabama • Chandler, Arizona • Redding, California + 17 more

Conditions: Idiopathic Intracranial Hypertension (IIH)
Interventions: Tirzepatide, Tirzepatide Placebo; Drug
Lead sponsor: Duke University; Other
Eligibility: 18 Years to 60 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Hypertension, Pulmonary, Altitude Sickness
Interventions: Riociguat; Drug
Lead sponsor: Richard Moon; Other
Eligibility: 18 Years to 40 Years
Enrollment: 28 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Glaucoma
Interventions: Brinzolamide 1% ophthalmic solution (Azopt), Placebo eye drops, Latanoprost 0.005% ophthalmic solution (Xalatan); Drug
Lead sponsor: Alcon Research; Industry
Eligibility: 35 Years and older
Enrollment: 86 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 1
States / cities: Fort Worth, Texas

Conditions: Pulmonary Hypertension
Interventions: Oral treprostinil (UT-15C) Sustained Release Tablets, Placebo; Drug · Other
Lead sponsor: United Therapeutics; Industry
Eligibility: 12 Years to 75 Years
Enrollment: 349 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2011
U.S. locations: 43
States / cities: Birmingham, Alabama • Phoenix, Arizona • Fresno, California + 34 more

Conditions: Prehypertension (elevated Blood Pressure) or Hypertension
Interventions: H1 receptor blockade: 540 mg (Allegra), H2 receptor blockade: 40 mg (Pepcid AC); Genetic
Lead sponsor: California Baptist University; Other
Eligibility: 18 Years to 30 Years · Male only
Enrollment: 10 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024
U.S. locations: 1
States / cities: Riverside, California

Conditions: ASCVD, Hyperlipidemia, Hypertension
Interventions: Referral to the Duke Cardiometabolic Prevention Clinic; Other
Lead sponsor: Duke University; Other
Eligibility: 18 Years and older
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Hypertension, Non-Adherence, Patient
Interventions: Wellth Smartphone App, Targeted Incentives, Non-Restricted Incentives; Behavioral
Lead sponsor: Wellth Inc.; Industry
Eligibility: 50 Years and older
Enrollment: 97 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 3
States / cities: San Diego, California • New York, New York

Conditions: Glaucoma, Primary Open Angle Glaucoma, Secondary Glaucoma, Neovascular Glaucoma
Interventions: Mitomycin-C, Balanced Salt Solution, Ahmed Glaucoma Valve Implant; Drug · Other · Procedure
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years to 85 Years
Enrollment: 119 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2020
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Insulin Sensitivity, Flow-mediated Dilation, Arterial Stiffness
Interventions: Not listed
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 14 Years to 18 Years · Female only
Enrollment: 62 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2013
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Diabetes Mellitus, Type 2, Hyperlipidemia, Hypertension
Interventions: Physician counseling for health behavior change; Behavioral
Lead sponsor: The University of Texas Health Science Center at San Antonio; Other
Eligibility: 18 Years to 99 Years
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2003
U.S. locations: 6
States / cities: Corpus Christi, Texas • Harlingen, Texas • Laredo, Texas + 2 more

Conditions: Diabetes Mellitus, Type 2, Hypertension
Interventions: Empagliflozin low dose, placebo, Empagliflozin high dose; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years and older
Enrollment: 166 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 92
States / cities: Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 62 more

Conditions: Hypertension
Interventions: OWL-Hypertension 8 Wk Trial; Behavioral
Lead sponsor: Paula Gardiner; Other
Eligibility: 18 Years and older
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019
U.S. locations: 1
States / cities: Worcester, Massachusetts

Conditions: Hypertension, Pulmonary, Heart Failure
Interventions: Preventing pulm HTN during exercise; Procedure
Lead sponsor: Cardioflow Technologies, LLC; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 1
States / cities: Mountain View, California

Conditions: High Blood Pressure, Hypertension
Interventions: Educational Intervention Based on Protection Motivation Theory to Improve Knowledge and Promote Nonpharmacological Approaches to Prevent and Manage Hypertension among Adults; Other
Lead sponsor: Kansas State University; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2023
U.S. locations: 1
States / cities: Manhattan, Kansas

Conditions: Glaucoma
Interventions: 5-fluorouracil, Mitomycin C; Drug
Lead sponsor: Indiana University; Other
Eligibility: Not listed
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2007
U.S. locations: 2
States / cities: Indianapolis, Indiana

Conditions: Glaucoma, Glaucoma Eye, Glaucoma, Open-Angle
Interventions: Lumega-Z, Dorzolamide Hcl 2% Oph Soln, Placebo; Dietary Supplement · Drug · Other
Lead sponsor: University of the Incarnate Word; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Preeclampsia
Interventions: Diffusion Lung Capacity (DLCO), Vascular Challenge, Video Imaging, Specimen Collections; Other
Lead sponsor: Indiana University; Other
Eligibility: 26 Weeks and older
Enrollment: 292 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2020
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: Intracranial Pressure Increase
Interventions: Pictor; Diagnostic Test
Lead sponsor: Duke University; Other
Eligibility: Up to 21 Years
Enrollment: 3 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Postpartum Complication
Interventions: Intensive Education, Enhanced Virtual Care; Other
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 18 Years and older · Female only
Enrollment: 3,500 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2028
U.S. locations: 2
States / cities: Atlanta, Georgia • Dallas, Texas

Conditions: Hypertension
Interventions: Inspiratory muscle strength training; Behavioral
Lead sponsor: University of Arizona; Other
Eligibility: 50 Years and older
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024
U.S. locations: 1
States / cities: Tucson, Arizona

Conditions: Asthma, Coronary Artery Disease, Diabetes, Hypertension, Congestive Heart Failure
Interventions: Reports, Reports and Notices, Usual care; Other
Lead sponsor: Duke University; Other
Eligibility: Not listed
Enrollment: 8,422 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Hypertension
Interventions: Screen-Educate, Screen-Educate and Intensify Treatment; Other
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years to 80 Years
Enrollment: 1,819 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Hypertension, Stroke (CVA) or TIA
Interventions: Daily Blood Pressure Monitoring; Behavioral
Lead sponsor: AIRx Health, Inc.; Other
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Stanford, California

Search by objective public record fields.

A Comparison of Bimatoprost SR to Selective Laser Trabeculoplasty in Patients With Open-Angle Glaucoma or Ocular Hypertension

Tirzepatide in Idiopathic Intracranial Hypertension Trial

Efficacy Study of Riociguat and Its Effects on Exercise Performance and Pulmonary Artery Pressure at High Altitude

A Comparison of Azopt Versus Placebo Added to Xalatan in Patients With Elevated Intraocular Pressure (IOP) on a Prostaglandin

FREEDOM - M: Oral Treprostinil as Monotherapy for the Treatment of Pulmonary Arterial Hypertension (PAH)

Effect of Aerobic Exercise with Blood Flow Restriction on Post-exercise Hypotension in Young Adults: the Role of Histamine Receptors

Duke Cardiometabolic Prevention Clinic's Impact on High-risk Cardiovascular Patients With Uncontrolled Risk Factors

Telehealth Intervention for Improved Blood Pressure Control With Targeted Incentives

Ahmed Glaucoma Valve Surgery With Mitomycin-C

Vitamin D, Insulin Sensitivity, and Vascular Associations in Adolescents

A Brief Intervention to Improve Medication Knowledge and Adherence Among Family Medicine Patients in South Texas

24 Week Efficacy and Safety Study of Empagliflozin (BI 10773) in Hypertensive Black/African American Patients With Type 2 Diabetes Mellitus and Hypertension

Reducing Disparities in the Treatment of Hypertension Using the OWL mHealth Tool

The Evaluation and Treatment of Elevated Left-Sided Filling Pressures by Balloon Inflation Within the IVC

Using Nonpharmacological Approaches in Hypertension Prevention and Management

Outcomes of Intraoperative 5-Fluorouracil Versus Mitomycin C

Augmented Macular Pigment-containing Nutraceutical and Central Visual Function

Anti-Angiogenic Preeclampsia Milieu Impairs Infant Lung and Vascular Development

Ocular Screening in Children and Young Adults at Risk for Increased Intracranial Pressure

IMPACT: Improving Maternal Postpartum Access to Care Through Telemedicine

Reduced Volume of Inspiratory Resistance Training

Care Transitions for Complex Patient - Cycle 1 and Cycle 2

Screen-and-treat Program for Chronic Kidney Disease- High Risk Persons

Effectiveness of BP Remote Monitoring With Virtual Physician Management in Hypertensive Patients.